Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2033

Annual patent cliff calendar for 2033 — US pharmaceutical patents by expiration date.

Patents
1,330

Quick answer

1,330 indexed pharmaceutical patents have expiration dates in 2033. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8551945

    Methods and compositions for treating neuropathies

    Sangamo Biosciences, Inc. · Granted Tue Oct 08 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8551966

    Chemical compounds

    University College Cardiff Consultants Limited · Granted Tue Oct 08 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. DE 102012205493

    Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem

    ACINO AG [DE] · Granted Thu Oct 10 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8557839

    Fused ring azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8557245

    Methods for treating bone cancer by administering a nerve growth factor antagonist antibody

    Regents of the University of Minnesota · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8557290

    Multifunction nanoconjugates for imaging applications and targeted treatment

    Northwestern University · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8557800

    Sphingosine kinase inhibitors

    Apogee Biotechnology Corporation · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8557818

    Compounds useful as protein kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8557978

    Cross-linked glycopeptide-cephalosporin antibiotics

    Theravance, Inc. · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8557250

    Methods for preparing complex multivalent immunogenic conjugates

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8556882

    Inducible interleukin-12

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8557291

    Abuse-deterrent pharmaceutical compositions of opioids and other drugs

    Collegium Pharmaceutical, Inc. · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8557298

    Medicaments for chemotherapeutic treatment of disease

    Provectus Pharmatech, Inc. · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8557552

    Selective neuronal nitric oxide synthase inhibitors

    Northwestern University · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8557295

    Use of cellular extracts for skin rejuvenation

    REGENICS AS · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8557812

    Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8557788

    Prevention of tissue ischemia and related compositions

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8557790

    A3 adenoside receptor agonists for the reduction of intraocular pressure

    CAN-FITE BIOPHARMA LTD. · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8557789

    Method of treating inflammatory arthropathies with supressors of CPG oligonucleotides

    The United States of America as represented by the Secretary of the Development of Health and Human Services · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8557805

    Fused ring compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8557822

    Carboxamide, sulfonamide and amine compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8557833

    Aminopyrimidines useful as kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8557844

    Substrate reduction therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8557859

    Immunomodulatory compositions

    Summit (Wales) Limited · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8557969

    Compositions and methods for regulating cardiac performance

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8557997

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8557764

    Methods of modulating immune function

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8557806

    Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. DE 102012007671

    Pellets mit hohem Wirkstoffgehalt

    ACINO PHARMA AG [CH] · Granted Thu Oct 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Oct 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8563515

    Tight junction protein modulators and uses thereof

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8563569

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8563575

    Fused heterocyclic compounds

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8562965

    Polymer derivatives comprising an acetal or ketal branching point

    Nektar Therapeutics · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8563573

    Azaindole derivatives as CFTR modulators

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8563576

    Tri-cyclic pyrazolopyridine kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8563593

    Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8563599

    Methods for synthesizing glycinols, glyceollins I and II, compositions of selected intermediates, and therapeutic uses thereof

    THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF AGRICULTURE · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8563026

    Protein-based artificial retinas

    UNIVERSITY OF CONNECTICUT · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8563028

    Ophthalmic device, and method of use thereof, for increasing ocular boundary lubrication

    The Regents of the University of California · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8563269

    Modified antibody compositions, methods of making and using thereof

    CytomX Therapeutics, Inc. · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8563512

    Neprilysin inhibitors

    Theravance, Inc. · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8563731

    Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor

    Almirall, S.A. · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8563595

    Treatment of cancer with complex organic-inorganic pigment compositions

    The Board of Regents of the University of Texas System · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8563559

    Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8563692

    Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities

    The Regents of the University of California · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8563730

    Pyrazole and fused pyrazole glucokinase activators

    Takeda San Diego, Inc. · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8562954

    Dental compositions with sensitivity relief

    DISCUS DENTAL, LLC · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8563716

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2033?

1,330 published patents in our USPTO index have expiration dates falling in calendar year 2033.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.